Opendata, web and dolomites


Study of tau strains to understand the phenotypic diversity of Alzheimer’s disease: A step toward personalized therapies

Total Cost €


EC-Contrib. €






 DIVE into AD project word cloud

Explore the words cloud of the DIVE into AD project. It provides you a very rough idea of what is the project "DIVE into AD" about.

brain    pathology    single    progression    variants    confirmed    ageing    heterogeneity    beta    patient    determinants    responsible    protein    patients    deposition    conformers    propagate    strains    native    alzheimer    event    seem    respective    signatures    morphology    majority    neuron    gender    understand    innovative    causative    treatment    diversity    expression    template    cognition    differences    behaves    tau    care    discrete    aggregates    potentially    vast    repertoire    sensitively    accumulation    biomarkers    optimize    millions    pathophysiology    samples    postulate    disease    cerebrospinal    variability    metabolism    spread    suffering    modifies    fidelity    technologies    hallmark    phenotypes    patterns    deep    unsuccessfully    therapeutic    biosensor    plan    shown    generate    modern    treat    lines    neuronal    societies    human    19    dementia    fluid    therapies    neurodegeneration    pathological    correlates    conformation    citizens    individual    detect    rate    ad    vulnerability    clinical    2050    ultimately    prion    peptide    course    cell   

Project "DIVE into AD" data sheet

The following table provides information about the project.


Organization address
city: GENEVE
postcode: 1211

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 278˙840 €
 EC max contribution 278˙840 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-GF
 Starting year 2020
 Duration (year-month-day) from 2020-08-01   to  2023-07-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITE DE GENEVE CH (GENEVE) coordinator 278˙840.00


 Project objective

Dementia represents a major challenge for our ageing societies. The number of citizens suffering from dementia in the EU is expected to reach 19 millions by 2050. Alzheimer’s disease (AD) is responsible for the vast majority of dementia cases. However there is still not a single available treatment that modifies the course of disease. Therefore, the development of innovative approaches to better understand the pathophysiology and ultimately treat patients must be a priority. This project aims to understand the determinants of the diversity of AD clinical phenotypes through the deep analysis of pathological variants of the tau protein. As the accumulation of Aβ peptide has long been considered a causative event in AD, most therapeutic approaches have targeted Aβ metabolism, but unsuccessfully. Modern biomarkers, have confirmed that the brain deposition of tau pathology, the other hallmark of AD, correlates much better with human cognition and neurodegeneration. Recently, it was shown that tau behaves like a prion and can spread from one neuron to another. Moreover, tau strains or conformers seem to template native tau and propagate the pathological conformation with high fidelity. Discrete tau strains generate distinct aggregates morphology or patterns of neuronal vulnerability. I postulate that different strains of tau are responsible for the variability of AD and may determine the progression rate, gender differences or clinical expression. Therefore, my objective is to develop the technologies to identify tau strains signatures in distinct AD phenotypes. In particular, I plan to develop and optimize biosensor cell lines that sensitively detect tau strains from human brain samples and cerebrospinal fluid, and characterize respective repertoire of tau strains. Understanding AD heterogeneity would potentially increase our ability to take care of every individual patient. In addition, this work could lead to the development of biomarkers and novel targeted therapies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DIVE INTO AD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DIVE INTO AD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MS4Drug (2019)

An Innovative Mass Spectrometry-Based Workflow for Drug Discovery

Read More  

EVENTS (2020)

Affective work-related daily events, and changing characteristics of the work context: New challenges for management practices to deliver employees’ well-being and workplace performance

Read More  


Simulations of Topological Phases in Superconducting Circuits

Read More